Results 161 to 170 of about 4,164 (194)

Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study. [PDF]

J Bone Miner Res
Vilaca T, Lui LY, Schini M, Ewing SK, Thompson A, Vittinghoff E, Bauer DC, Black DM, Bouxsein ML, Eastell R.   +9 more
europepmc   +1 more source

The Conundrum of Medical Fracture Prevention in Chronic Kidney Disease-Summary of the Evidence and Pragmatic Clinical Guidance. [PDF]

J Clin Med
Schietzel S, Huynh-Do U.
europepmc   +1 more source

Romosozumab for osteoporosis.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nonresponder Considerations for Romosozumab Treatment

Calcified Tissue International, 2023
Romosozumab can increase bone mineral density (BMD) in patients with osteoporosis, but some patients do not respond to it. This study aimed to identify risk factors for being a nonresponder to romosozumab treatment. This retrospective observational study included 92 patients.
Ayako Tominaga, Keiji Wada, Ken Okazaki, Hideharu Nishi, Yasushi Terayama, Shuji Shimamoto, Yasuteru Kodama, Yoshiharu Kato   +7 more
openaire   +2 more sources

Romosozumab

Reactions Weekly
  +9 more sources

Utilization of Romosozumab in Primary Care

Journal of Pharmacy Technology, 2023
Objective: The objective of the study is to highlight the role and safety of romosozumab in patients at high risk of fractures in primary care. Data Sources: A systemic database search of PubMed/MEDLINE, ClinicalTrials.gov, and Cochrane Library was conducted for articles with keywords romosozumab, osteoporosis, and safety between inception and July ...
Soon Hye Yang, Neha Mittal, Amanda L. Bell, Christian E. Bell   +3 more
openaire   +2 more sources

Romosozumab: First Global Approval

Drugs, 2019
Romosozumab (EVENITY™) is a humanised monoclonal antibody against sclerostin being developed by Amgen and UCB for the treatment of osteoporosis. On the basis of favourable results from several phase III trials in postmenopausal women with osteoporosis, and a single trial in men with osteoporosis, romosozumab is being considered for marketing approval ...
openaire   +2 more sources

Romosozumab in the Treatment of Osteoporosis

Immunotherapy, 2020
Osteoporosis is a disease characterized by weakening of the bone architecture, which leads to an increased risk of fracture. There has been interest in the development of osteoanabolic agents that can increase bone mass and reverse the deteriorating architecture of osteoporotic bone.
Alexandra O Kobza, Alexandra Papaioannou, Arthur N Lau, Jonathan D Adachi   +3 more
openaire   +2 more sources

Romosozumab: A Review in Postmenopausal Osteoporosis

Drugs & Aging, 2020
Romosozumab (Evenity®), a humanized monoclonal antibody, promotes bone formation and inhibits bone resorption by inhibiting sclerostin, a protein involved in the regulation of bone formation. Subcutaneous romosozumab is approved in several countries, including those of the EU for treating severe osteoporosis as well as in the USA for osteoporosis in ...
Julia, Paik, Lesley J, Scott
openaire   +2 more sources